Michael Nanna, MD, MHS, FSCAI, FACC
Assistant Professor of Internal Medicine (Cardiovascular Medicine)Cards
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileContact Info
Cardiovascular Medicine
333 Cedar St.
New Haven, CT 06510
United States
About
Titles
Assistant Professor of Internal Medicine (Cardiovascular Medicine)
Biography
Dr. Nanna is an Interventional Cardiologist specializing in coronary interventions, with a focus on the care of older adults living with multiple chronic conditions. Dr. Nanna graduated Stony Brook University School of Medicine as a member of both the Alpha Omega Alpha and the Arnold P. Gold Foundation honor societies. He completed his training in internal medicine and served as a chief resident at Yale New Haven Hospital before training in Cardiology and Interventional Cardiology at Duke University Medical Center. In addition, he completed a Master of Health Sciences in Clinical Research degree through the Clinical Research Training Program at Duke University School of Medicine.
His research interests center around improving risk prediction, treatment utilization and shared decision-making for older adults at risk for or living with cardiovascular disease. He is the recipient of several awards including a GEMSSTAR (Grants for Early Medical/Surgical Specialists’ Transition to Aging Research) award from the NIH National Institute on Aging to address the medical needs of older adult patients at high risk for cardiovascular disease and dementia, as well as a geriatric cardiology professional development award from the American College of Cardiology Foundation supported by the George F. and Ann Harris Bellows Foundation. In collaboration with the Yale Pepper Center, he is the national PI for the LIVEBETTER trial, a randomized trial of anti-anginal therapies in older adults with stable ischemic heart disease and multiple chronic conditions funded by the Patient-Centered Outcomes Research Institute (PCORI). Most recently, he was selected as a Beeson Scholar by the National Institute on Aging, receiving a K76 award to investigate the treatment effects of cardiovascular medications on cognitive trajectory in older adults. Dr. Nanna currently serves as an Associate Editor at the American Heart Journal & JACC Advances. He has served as a reviewer for a number of scholarly journals including JAMA, JACC, and Circulation.
Appointments
Cardiovascular Medicine
Assistant ProfessorPrimary
Other Departments & Organizations
- Cardiovascular Medicine
- Internal Medicine
- Yale Medicine
Education & Training
- Fellowship, Interventional Cardiology
- Duke University Medical Center (2021)
- MHS
- Duke University School of Medicine, Clinical Research (2020)
- Cardiovascular Research Fellowship
- Duke University/Duke Clinical Research Institute (2020)
- Fellowship, Cardiology
- Duke University Medical Center (2019)
- Chief Resident
- Yale School of Medicine (2016)
- Internship/Residency, Internal Medicine
- Yale New Haven Hospital (2015)
- MD
- Stony Brook School of Medicine (2012)
- BA
- Colgate University (2008)
Research
Overview
Medical Research Interests
ORCID
0000-0001-5745-1636
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Dae Yong Park, MD, MSCI
Sarwat Chaudhry, MD
Mary Geda, BSN, MSN, RN
Harlan Krumholz, MD, SM
Marc Samsky, MD, FACC
Carlos Mena-Hurtado, MD, FACC, FSCAI, FAHA
Publications
2025
Bridging Care Gaps for Older Women Undergoing Percutaneous Coronary Intervention
Kalra K, Sampath R, Cigarroa N, Sutton N, Damluji A, Nanna M. Bridging Care Gaps for Older Women Undergoing Percutaneous Coronary Intervention. Interventional Cardiology Clinics 2025, 14: 69-79. PMID: 39537289, DOI: 10.1016/j.iccl.2024.08.006.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and Concepts
2024
Short versus 1-Year Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: An Updated Systematic Review and Meta-Analysis
Joseph M, Krishna M, Ezenna C, Pereira V, Ismayl M, Nanna M, Bangalore S, Goldsweig A. Short versus 1-Year Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: An Updated Systematic Review and Meta-Analysis. The American Journal Of Cardiology 2024 PMID: 39577682, DOI: 10.1016/j.amjcard.2024.10.038.Peer-Reviewed Original ResearchConceptsPost-percutaneous coronary interventionAcute coronary syndromeDrug-eluting stentsPercutaneous coronary interventionCoronary interventionAcute coronary syndrome cohortCochrane Central databasesShortening DAPT durationMonths post-percutaneous coronary interventionClopidogrel subgroupRandomized controlled trialsNo significant differenceCoronary syndromeMonotherapyTicagrelor monotherapyDAPT durationShorter DAPTBleedingStent thrombosisP2Y12iMyocardial infarctionControlled trialsSubgroup interactionsDAPTMeta-analysisThe Impact of Frailty on Patients With AF and HFrEF Undergoing Catheter Ablation A Nationwide Population Study
Mark J, Colombo R, Alfonso C, Llanos A, Collado E, Larned J, Giese G, Dyal M, Nanna M, Damluji A. The Impact of Frailty on Patients With AF and HFrEF Undergoing Catheter Ablation A Nationwide Population Study. JACC Advances 2024, 3: 101358. PMID: 39600986, PMCID: PMC11588852, DOI: 10.1016/j.jacadv.2024.101358.Peer-Reviewed Original ResearchAltmetricConceptsAdverse cardiovascular eventsCatheter ablationAtrial fibrillationCardiovascular eventsHeart failureFrail patientsHospital lengthNonfrail patientsReducing major adverse cardiovascular eventsAssociated with worse outcomesMajor adverse cardiovascular eventsReduced ejection fractionHospital length of stayIn-hospital mortalityLonger hospital lengthAssociated with increased oddsDischarge dispositionInfluence of frailtyMultivariate regression analysisNationwide Inpatient SampleImpact of frailtyLength of stayPrevalence of frailtyEjection fractionJohns Hopkins Adjusted Clinical GroupsInvasive Versus Conservative Strategy in Older Adults ≥75 Years of Age With Non-ST-segment-Elevation Acute Coronary Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Rout A, Moumneh M, Kalra K, Singh S, Garg A, Kunadian V, Biscaglia S, Alkhouli M, Rymer J, Batchelor W, Nanna M, Damluji A. Invasive Versus Conservative Strategy in Older Adults ≥75 Years of Age With Non-ST-segment-Elevation Acute Coronary Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal Of The American Heart Association 2024, 13: e036151. PMID: 39494560, DOI: 10.1161/jaha.124.036151.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsNon-ST segment elevation acute coronary syndromeAcute coronary syndromeComposite of deathBurden of geriatric conditionsRandomized controlled trialsCoronary syndromeMyocardial infarctionYears of ageInvasive strategyOlder adultsControlled trialsGeriatric conditionsOlder patientsCardiovascular deathOdds ratioMeta-analysis of randomized controlled trialsNon-ST segment elevationSecondary end pointsMeta-analysisFixed effects meta-analysisAll-cause deathEffects meta-analysisYounger patientsFollow-upDecreased riskThe Impact of Socioeconomic Status and Diagnostic Timeline on Clinical Outcomes in ATTR Cardiomyopathy
Chi K, Gallegos-Kattán C, Sikand N, Samsky M, Nanna M. The Impact of Socioeconomic Status and Diagnostic Timeline on Clinical Outcomes in ATTR Cardiomyopathy. Journal Of The American College Of Cardiology 2024, 84: e289-e290. PMID: 39505422, DOI: 10.1016/j.jacc.2024.07.050.Peer-Reviewed Original ResearchOral anticoagulants or antiplatelets for cryptogenic stroke: a systematic review and meta-analysis
Chi K, Song J, Zarif T, Chiang C, Lee P, Chang Y, Nanna M, Nanna M. Oral anticoagulants or antiplatelets for cryptogenic stroke: a systematic review and meta-analysis. European Heart Journal 2024, 45: ehae666.2309. DOI: 10.1093/eurheartj/ehae666.2309.Peer-Reviewed Original ResearchConceptsLeft atrial diameterRelevant randomized controlled trialsPatent foramen ovaleNAVIGATE ESUS trialOral anticoagulantsOral anticoagulant useRecurrent ischemic strokeCryptogenic strokeIschemic strokeMeta-analysisSubgroup analysisESUS patientsHazard ratioSafety of oral anticoagulantsInternational Society of ThrombosisSociety of ThrombosisOptimal antithrombotic strategyAtrial cardiopathyDiagnostic work-upRE-SPECT ESUSElectronic databases of PubMedCryptogenic stroke patientsSources of cardioembolismRandom-effects meta-analysisSystematic reviewMortality effects of beta-blockers on myocardial infarction in patients without reduced ejection fraction or heart failure in the contemporary reperfusion era : a systematic review and meta-analysis
Y K, Lee P, Chowdhury I, Schwartz R, Kang Y, Mangalesh S, Babapour G, Akman Z, Chang Y, Song J, Lessa Y, Damluji A, Nanna M, Nanna M. Mortality effects of beta-blockers on myocardial infarction in patients without reduced ejection fraction or heart failure in the contemporary reperfusion era : a systematic review and meta-analysis. European Heart Journal 2024, 45: ehae666.1640. DOI: 10.1093/eurheartj/ehae666.1640.Peer-Reviewed Original ResearchConceptsRandomized controlled trialsReduced ejection fractionBeta-blockersEjection fractionHeart failureMortality benefitReduced EFMeta-regressionEF patientsPreserved EFBB usersReperfusion eraMeta-analysisSubgroup analysisSystematic reviewPost-MIPost-MI careEffect of beta-blockersIncreased all-cause mortalityHistory of HFEvent-free periodAll-cause mortalityTemporal trendsStudy inclusion periodModern randomized controlled trialsPrognostic Value of Cardiovascular Biomarkers
Mangalesh S, Nanna M. Prognostic Value of Cardiovascular Biomarkers. JAMA 2024, 332: 1302-1303. PMID: 39292479, DOI: 10.1001/jama.2024.16522.Peer-Reviewed Original ResearchAltmetricMeSH KeywordsValidating the PREVENT Equations—A Contemporary Update to Cardiovascular Risk Assessment
Mangalesh S, Nanna M. Validating the PREVENT Equations—A Contemporary Update to Cardiovascular Risk Assessment. JAMA Network Open 2024, 7: e2438284. PMID: 39392636, DOI: 10.1001/jamanetworkopen.2024.38284.Peer-Reviewed Original ResearchAltmetricBeta-blockers for secondary prevention following myocardial infarction in patients without reduced ejection fraction or heart failure: an updated meta-analysis
Chi K, Lee P, Chowdhury I, Akman Z, Mangalesh S, Song J, Satish V, Babapour G, Kang Y, Schwartz R, Chang Y, Borkowski P, Nanna M, Damluji A, Nanna M. Beta-blockers for secondary prevention following myocardial infarction in patients without reduced ejection fraction or heart failure: an updated meta-analysis. European Journal Of Preventive Cardiology 2024, zwae298. PMID: 39298680, DOI: 10.1093/eurjpc/zwae298.Peer-Reviewed Original ResearchAltmetricConceptsReduced ejection fractionBeta-blockersEjection fractionHeart failureMortality benefitBB useReduced EFCV mortalityPost-MIRandom-effects meta-analysisMeta-analysisHistory of HFAll-cause mortalityTemporal trendsPrespecified subgroup analysesEvent-free periodCardiovascular (CVIncreased CV mortalityStudy inclusion periodPost-myocardial infarctionContemporary dataAssociated with detrimental effectsNon-significant trendSecondary preventionBB users
Clinical Trials
Current Trials
LIVEBETTER (a trial comparing the effectiveness and tolerability of medications in older adults with stable angina and multiple chronic conditions)
HIC ID2000034470RolePrincipal InvestigatorPrimary Completion Date05/30/2027Recruiting Participants
Academic Achievements & Community Involvement
activity American Heart Journal
Journal ServiceAssociate EditorDetails08/09/2021 - Presentactivity JAMA
Journal ServiceReviewerDetails12/03/2019 - Presentactivity JAMA Internal Medicine
Journal ServiceReviewerDetails08/05/2020 - Presentactivity JAMA Cardiology
Journal ServiceReviewerDetails05/20/2020 - Presentactivity JACC
Journal ServiceReviewerDetails01/05/2020 - Present
Clinical Care
Overview
Clinical Specialties
Fact Sheets
Heart Attack (Myocardial Infarction)
Learn More on Yale MedicineHeart Disease in Women
Learn More on Yale MedicineBlood Clots in Veins, Heart and Lungs
Learn More on Yale MedicineChest Pain
Learn More on Yale Medicine
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews
News
- November 18, 2024Source: The Seattle Times
8 Factors That Can Raise Your Heart Disease Risk
- November 07, 2024Source: The New York Times
8 Factors That Can Raise Your Heart Disease Risk
- November 05, 2024
Yale Researchers at American Heart Association Scientific Session 2024
- October 24, 2024
New Analytics Center for Cardiovascular Medicine
Get In Touch
Contacts
Cardiovascular Medicine
333 Cedar St.
New Haven, CT 06510
United States
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.